VIAF

Virtual International Authority File

Search

Leader     00000nz a2200037n 45 0
001     WKP|Q125174081  (VIAF cluster)  (Authority/Source Record)
003     WKP
005     20241121000238.0
008     241121nneanz||abbn n and d
035 ‎‡a  (WKP)Q125174081‏
035 ‎‡a  (OCoLC)Q125174081‏
100 0 ‎‡a  Maria Almira Correia‏ ‎‡c  researcher‏ ‎‡9  en‏
670 ‎‡a  Author's A Novel Mechanism For NF-κB Activation Via IκB Aggregation: Implications For Hepatic Mallory-Denk-Body Induced Inflammation‏
670 ‎‡a  Author's A role for protein phosphorylation in cytochrome P450 3A4 ubiquitin-dependent proteasomal degradation‏
670 ‎‡a  Author's Alcohol use and HIV pharmacotherapy.‏
670 ‎‡a  Author's Cellular proteolytic systems in P450 degradation: evolutionary conservation from Saccharomyces cerevisiae to mammalian liver‏
670 ‎‡a  Author's Characterization of the physiological turnover of native and inactivated cytochromes P450 3A in cultured rat hepatocytes: a role for the cytosolic AAA ATPase p97?‏
670 ‎‡a  Author's CHIP(-/-)-Mouse Liver: Adiponectin-AMPK-FOXO-Activation Overrides CYP2E1-Elicited JNK1-Activation, Delaying Onset of NASH: Therapeutic Implications‏
670 ‎‡a  Author's CYP3A4-Mediated carbamazepine (CBZ) metabolism: formation of a covalent CBZ-CYP3A4 adduct and alteration of the enzyme kinetic profile‏
670 ‎‡a  Author's CYP3A4 ubiquitination by gp78 (the tumor autocrine motility factor receptor, AMFR) and CHIP E3 ligases‏
670 ‎‡a  Author's Cytochrome P450 endoplasmic reticulum-associated degradation (ERAD): therapeutic and pathophysiological implications‏
670 ‎‡a  Author's Cytochrome P450 regulation: the interplay between its heme and apoprotein moieties in synthesis, assembly, repair, and disposal‏
670 ‎‡a  Author's Cytochrome P450 ubiquitination: branding for the proteolytic slaughter?‏
670 ‎‡a  Author's Differential oxidation of mifepristone by cytochromes P450 3A4 and 3A5: selective inactivation of P450 3A4.‏
670 ‎‡a  Author's Endoplasmic reticulum-associated degradation of cytochrome P450 CYP3A4 in Saccharomyces cerevisiae: further characterization of cellular participants and structural determinants‏
670 ‎‡a  Author's Heme-reversible impairment of CYP2B1/2 induction in heme-depleted rat hepatocytes in primary culture: translational control by a hepatic alpha-subunit of the eukaryotic initiation factor kinase?‏
670 ‎‡a  Author's Hemin-mediated restoration of allylisopropylacetamide-inactivated CYP2B1: a role for glutathione and GRP94 in the heme-protein assembly‏
670 ‎‡a  Author's Hepatic CYP3A suppression by high concentrations of proteasomal inhibitors: a consequence of endoplasmic reticulum (ER) stress induction, activation of RNA-dependent protein kinase-like ER-bound eukaryotic initiation factor 2alpha (eIF2alpha)-kinase‏
670 ‎‡a  Author's Hepatic cytochrome P450 degradation: mechanistic diversity of the cellular sanitation brigade‏
670 ‎‡a  Author's Hepatic cytochrome P450 ubiquitination: conformational phosphodegrons for E2/E3 recognition?‏
670 ‎‡a  Author's Hepatic cytochromes P450: structural degrons and barcodes, posttranslational modifications and cellular adapters in the ERAD-endgame‏
670 ‎‡a  Author's Hepatic heme-regulated inhibitor (HRI) eukaryotic initiation factor 2alpha kinase: a protagonist of heme-mediated translational control of CYP2B enzymes and a modulator of basal endoplasmic reticulum stress tone‏
670 ‎‡a  Author's Human liver cytochrome P450 3A4 ubiquitination: molecular recognition by UBC7-gp78 autocrine motility factor receptor and UbcH5a-CHIP-Hsc70-Hsp40 E2-E3 ubiquitin ligase complexes‏
670 ‎‡a  Author's Impaired dexamethasone-mediated induction of tryptophan 2,3-dioxygenase in heme-deficient rat hepatocytes: translational control by a hepatic eIF2alpha kinase, the heme-regulated inhibitor‏
670 ‎‡a  Author's Induction via Functional Protein Stabilization of Hepatic Cytochromes P450 upon gp78/Autocrine Motility Factor Receptor (AMFR) Ubiquitin E3-Ligase Genetic Ablation in Mice: Therapeutic and Toxicological Relevance‏
670 ‎‡a  Author's Inhibition of Cytochrome P450 Enzymes‏
670 ‎‡a  Author's Liver cytochrome P450 3A endoplasmic reticulum-associated degradation: a major role for the p97 AAA ATPase in cytochrome P450 3A extraction into the cytosol‏
670 ‎‡a  Author's Liver cytochrome P450 3A ubiquitination in vivo by gp78/autocrine motility factor receptor and C terminus of Hsp70-interacting protein‏
670 ‎‡a  Author's Liver cytochrome P450 3A ubiquitination in vivo by gp78/autocrine motility factor receptor and C terminus of Hsp70-interacting protein (CHIP) E3 ubiquitin ligases: physiological and pharmacological relevance‏
670 ‎‡a  Author's Molecular basis for catalysis and substrate-mediated cellular stabilization of human tryptophan 2,3-dioxygenase‏
670 ‎‡a  Author's Multisite phosphorylation of human liver cytochrome P450 3A4 enhances Its gp78- and CHIP-mediated ubiquitination: a pivotal role of its Ser-478 residue in the gp78-catalyzed reaction‏
670 ‎‡a  Author's Native CYP2C11: heterologous expression in Saccharomyces cerevisiae reveals a role for vacuolar proteases rather than the proteasome system in the degradation of this endoplasmic reticulum protein‏
670 ‎‡a  Author's Pathways of carbamazepine bioactivation in vitro. III. The role of human cytochrome P450 enzymes in the formation of 2,3-dihydroxycarbamazepine‏
670 ‎‡a  Author's Structure-function relationships of rat liver CYP3A9 to its human liver orthologs: site-directed active site mutagenesis to a progesterone dihydroxylase‏
670 ‎‡a  Author's The changing environment of graduate and postdoctoral training in drug metabolism: viewpoints from academia, industry, and government‏
670 ‎‡a  Author's Ubiquitin-dependent proteasomal degradation of human liver cytochrome P450 2E1: identification of sites targeted for phosphorylation and ubiquitination‏
670 ‎‡a  Author's Vacuolar degradation of rat liver CYP2B1 in Saccharomyces cerevisiae: further validation of the yeast model and structural implications for the degradation of mammalian endoplasmic reticulum P450 proteins.‏
670 ‎‡a  Author's Why Hepatic CYP2E1-Elevation by Itself Is Insufficient for Inciting NAFLD/NASH: Inferences from Two Genetic Knockout Mouse Models‏
919 ‎‡a  cyp3a4mediatedcarbamazepinecbzmetabolismformationofacovalentcbzcyp3a4adductandalterationoftheenzymekineticprofile‏ ‎‡A  CYP3A4-Mediated carbamazepine (CBZ) metabolism: formation of a covalent CBZ-CYP3A4 adduct and alteration of the enzyme kinetic profile‏ ‎‡9  1‏
919 ‎‡a  cyp3a4ubiquitinationbygp78thetumorautocrinemotilityfactorreceptoramfrandchipe3ligases‏ ‎‡A  CYP3A4 ubiquitination by gp78 (the tumor autocrine motility factor receptor, AMFR) and CHIP E3 ligases‏ ‎‡9  1‏
919 ‎‡a  cytochromep450endoplasmicreticulumassociateddegradationeradtherapeuticandpathophysiologicalimplications‏ ‎‡A  Cytochrome P450 endoplasmic reticulum-associated degradation (ERAD): therapeutic and pathophysiological implications‏ ‎‡9  1‏
919 ‎‡a  cytochromep450regulationtheinterplaybetweenitshemeandapoproteinmoietiesinsynthesisassemblyrepairanddisposal‏ ‎‡A  Cytochrome P450 regulation: the interplay between its heme and apoprotein moieties in synthesis, assembly, repair, and disposal‏ ‎‡9  1‏
919 ‎‡a  chipmouseliveradiponectinampkfoxoactivationoverridescyp2e1elicitedjnk1activationdelayingonsetofnashtherapeuticimplications‏ ‎‡A  CHIP(-/-)-Mouse Liver: Adiponectin-AMPK-FOXO-Activation Overrides CYP2E1-Elicited JNK1-Activation, Delaying Onset of NASH: Therapeutic Implications‏ ‎‡9  1‏
919 ‎‡a  cytochromep450ubiquitinationbrandingfortheproteolyticslaughter‏ ‎‡A  Cytochrome P450 ubiquitination: branding for the proteolytic slaughter?‏ ‎‡9  1‏
919 ‎‡a  differentialoxidationofmifepristonebycytochromesp4503a4and3a5selectiveinactivationofp4503a4‏ ‎‡A  Differential oxidation of mifepristone by cytochromes P450 3A4 and 3A5: selective inactivation of P450 3A4.‏ ‎‡9  1‏
919 ‎‡a  endoplasmicreticulumassociateddegradationofcytochromep450cyp3a4insaccharomycescerevisiaefurthercharacterizationofcellularparticipantsandstructuraldeterminants‏ ‎‡A  Endoplasmic reticulum-associated degradation of cytochrome P450 CYP3A4 in Saccharomyces cerevisiae: further characterization of cellular participants and structural determinants‏ ‎‡9  1‏
919 ‎‡a  hemereversibleimpairmentofcyp2b12inductioninhemedepletedrathepatocytesinprimaryculturetranslationalcontrolbyahepaticalphasubunitoftheeukaryoticinitiationfactorkinase‏ ‎‡A  Heme-reversible impairment of CYP2B1/2 induction in heme-depleted rat hepatocytes in primary culture: translational control by a hepatic alpha-subunit of the eukaryotic initiation factor kinase?‏ ‎‡9  1‏
919 ‎‡a  heminmediatedrestorationofallylisopropylacetamideinactivatedcyp2b1aroleforglutathioneandgrp94inthehemeproteinassembly‏ ‎‡A  Hemin-mediated restoration of allylisopropylacetamide-inactivated CYP2B1: a role for glutathione and GRP94 in the heme-protein assembly‏ ‎‡9  1‏
919 ‎‡a  hepaticcyp3asuppressionbyhighconcentrationsofproteasomalinhibitorsaconsequenceofendoplasmicreticulumerstressinductionactivationofrnadependentproteinkinaselikeerboundeukaryoticinitiationfactor2alphaeif2alphakinase‏ ‎‡A  Hepatic CYP3A suppression by high concentrations of proteasomal inhibitors: a consequence of endoplasmic reticulum (ER) stress induction, activation of RNA-dependent protein kinase-like ER-bound eukaryotic initiation factor 2alpha (eIF2alpha)-kinase‏ ‎‡9  1‏
919 ‎‡a  hepaticcytochromep450degradationmechanisticdiversityofthecellularsanitationbrigade‏ ‎‡A  Hepatic cytochrome P450 degradation: mechanistic diversity of the cellular sanitation brigade‏ ‎‡9  1‏
919 ‎‡a  hepaticcytochromep450ubiquitinationconformationalphosphodegronsfore2e3recognition‏ ‎‡A  Hepatic cytochrome P450 ubiquitination: conformational phosphodegrons for E2/E3 recognition?‏ ‎‡9  1‏
919 ‎‡a  hepaticcytochromesp450structuraldegronsandbarcodesposttranslationalmodificationsandcellularadaptersintheeradendgame‏ ‎‡A  Hepatic cytochromes P450: structural degrons and barcodes, posttranslational modifications and cellular adapters in the ERAD-endgame‏ ‎‡9  1‏
919 ‎‡a  hepatichemeregulatedinhibitorhrieukaryoticinitiationfactor2alphakinaseaprotagonistofhememediatedtranslationalcontrolofcyp2benzymesandamodulatorofbasalendoplasmicreticulumstresstone‏ ‎‡A  Hepatic heme-regulated inhibitor (HRI) eukaryotic initiation factor 2alpha kinase: a protagonist of heme-mediated translational control of CYP2B enzymes and a modulator of basal endoplasmic reticulum stress tone‏ ‎‡9  1‏
919 ‎‡a  humanlivercytochromep4503a4ubiquitinationmolecularrecognitionbyubc7gp78autocrinemotilityfactorreceptorandubch5achiphsc70hsp40e2e3ubiquitinligasecomplexes‏ ‎‡A  Human liver cytochrome P450 3A4 ubiquitination: molecular recognition by UBC7-gp78 autocrine motility factor receptor and UbcH5a-CHIP-Hsc70-Hsp40 E2-E3 ubiquitin ligase complexes‏ ‎‡9  1‏
919 ‎‡a  impaireddexamethasonemediatedinductionoftryptophan23dioxygenaseinhemedeficientrathepatocytestranslationalcontrolbyahepaticeif2alphakinasethehemeregulatedinhibitor‏ ‎‡A  Impaired dexamethasone-mediated induction of tryptophan 2,3-dioxygenase in heme-deficient rat hepatocytes: translational control by a hepatic eIF2alpha kinase, the heme-regulated inhibitor‏ ‎‡9  1‏
919 ‎‡a  inductionviafunctionalproteinstabilizationofhepaticcytochromesp450upongp78autocrinemotilityfactorreceptoramfrubiquitine3ligasegeneticablationinmicetherapeuticandtoxicologicalrelevance‏ ‎‡A  Induction via Functional Protein Stabilization of Hepatic Cytochromes P450 upon gp78/Autocrine Motility Factor Receptor (AMFR) Ubiquitin E3-Ligase Genetic Ablation in Mice: Therapeutic and Toxicological Relevance‏ ‎‡9  1‏
919 ‎‡a  inhibitionofcytochromep450enzymes‏ ‎‡A  Inhibition of Cytochrome P450 Enzymes‏ ‎‡9  1‏
919 ‎‡a  livercytochromep4503aendoplasmicreticulumassociateddegradationamajorroleforthep97aaaatpaseincytochromep4503aextractionintothecytosol‏ ‎‡A  Liver cytochrome P450 3A endoplasmic reticulum-associated degradation: a major role for the p97 AAA ATPase in cytochrome P450 3A extraction into the cytosol‏ ‎‡9  1‏
919 ‎‡a  livercytochromep4503aubiquitinationinvivobygp78autocrinemotilityfactorreceptorand100terminusofhsp70interactingprotein‏ ‎‡A  Liver cytochrome P450 3A ubiquitination in vivo by gp78/autocrine motility factor receptor and C terminus of Hsp70-interacting protein‏ ‎‡9  1‏
919 ‎‡a  livercytochromep4503aubiquitinationinvivobygp78autocrinemotilityfactorreceptorand100terminusofhsp70interactingproteinchipe3ubiquitinligasesphysiologicalandpharmacologicalrelevance‏ ‎‡A  Liver cytochrome P450 3A ubiquitination in vivo by gp78/autocrine motility factor receptor and C terminus of Hsp70-interacting protein (CHIP) E3 ubiquitin ligases: physiological and pharmacological relevance‏ ‎‡9  1‏
919 ‎‡a  molecularbasisforcatalysisandsubstratemediatedcellularstabilizationofhumantryptophan23dioxygenase‏ ‎‡A  Molecular basis for catalysis and substrate-mediated cellular stabilization of human tryptophan 2,3-dioxygenase‏ ‎‡9  1‏
919 ‎‡a  multisitephosphorylationofhumanlivercytochromep4503a4enhancesitsgp78andchipmediatedubiquitinationapivotalroleofitsser478residueinthegp78catalyzedreaction‏ ‎‡A  Multisite phosphorylation of human liver cytochrome P450 3A4 enhances Its gp78- and CHIP-mediated ubiquitination: a pivotal role of its Ser-478 residue in the gp78-catalyzed reaction‏ ‎‡9  1‏
919 ‎‡a  nativecyp2c11heterologousexpressioninsaccharomycescerevisiaerevealsaroleforvacuolarproteasesratherthantheproteasomesysteminthedegradationofthisendoplasmicreticulumprotein‏ ‎‡A  Native CYP2C11: heterologous expression in Saccharomyces cerevisiae reveals a role for vacuolar proteases rather than the proteasome system in the degradation of this endoplasmic reticulum protein‏ ‎‡9  1‏
919 ‎‡a  pathwaysofcarbamazepinebioactivationinvitro3theroleofhumancytochromep450enzymesintheformationof23dihydroxycarbamazepine‏ ‎‡A  Pathways of carbamazepine bioactivation in vitro. III. The role of human cytochrome P450 enzymes in the formation of 2,3-dihydroxycarbamazepine‏ ‎‡9  1‏
919 ‎‡a  structurefunctionrelationshipsofratlivercyp3a9toitshumanliverorthologssitedirectedactivesitemutagenesistoaprogesteronedihydroxylase‏ ‎‡A  Structure-function relationships of rat liver CYP3A9 to its human liver orthologs: site-directed active site mutagenesis to a progesterone dihydroxylase‏ ‎‡9  1‏
919 ‎‡a  changingenvironmentofgraduateandpostdoctoraltrainingindrugmetabolismviewpointsfromacademiaindustryandgovernment‏ ‎‡A  The changing environment of graduate and postdoctoral training in drug metabolism: viewpoints from academia, industry, and government‏ ‎‡9  1‏
919 ‎‡a  ubiquitindependentproteasomaldegradationofhumanlivercytochromep4502e1identificationofsitestargetedforphosphorylationandubiquitination‏ ‎‡A  Ubiquitin-dependent proteasomal degradation of human liver cytochrome P450 2E1: identification of sites targeted for phosphorylation and ubiquitination‏ ‎‡9  1‏
919 ‎‡a  vacuolardegradationofratlivercyp2b1insaccharomycescerevisiaefurthervalidationoftheyeastmodelandstructuralimplicationsforthedegradationofmammalianendoplasmicreticulump450proteins‏ ‎‡A  Vacuolar degradation of rat liver CYP2B1 in Saccharomyces cerevisiae: further validation of the yeast model and structural implications for the degradation of mammalian endoplasmic reticulum P450 proteins.‏ ‎‡9  1‏
919 ‎‡a  whyhepaticcyp2e1elevationbyitselfisinsufficientforincitingnafldnashinferencesfrom2geneticknockoutmousemodels‏ ‎‡A  Why Hepatic CYP2E1-Elevation by Itself Is Insufficient for Inciting NAFLD/NASH: Inferences from Two Genetic Knockout Mouse Models‏ ‎‡9  1‏
919 ‎‡a  characterizationofthephysiologicalturnoverofnativeandinactivatedcytochromesp4503ainculturedrathepatocytesaroleforthecytosolicaaaatpasep97‏ ‎‡A  Characterization of the physiological turnover of native and inactivated cytochromes P450 3A in cultured rat hepatocytes: a role for the cytosolic AAA ATPase p97?‏ ‎‡9  1‏
919 ‎‡a  cellularproteolyticsystemsinp450degradationevolutionaryconservationfromsaccharomycescerevisiaetomammalianliver‏ ‎‡A  Cellular proteolytic systems in P450 degradation: evolutionary conservation from Saccharomyces cerevisiae to mammalian liver‏ ‎‡9  1‏
919 ‎‡a  alcoholuseandhivpharmacotherapy‏ ‎‡A  Alcohol use and HIV pharmacotherapy.‏ ‎‡9  1‏
919 ‎‡a  roleforproteinphosphorylationincytochromep4503a4ubiquitindependentproteasomaldegradation‏ ‎‡A  A role for protein phosphorylation in cytochrome P450 3A4 ubiquitin-dependent proteasomal degradation‏ ‎‡9  1‏
919 ‎‡a  novelmechanismfornfκbactivationviaiκbaggregationimplicationsforhepaticmallorydenkbodyinducedinflammation‏ ‎‡A  A Novel Mechanism For NF-κB Activation Via IκB Aggregation: Implications For Hepatic Mallory-Denk-Body Induced Inflammation‏ ‎‡9  1‏
996 ‎‡2  PTBNP|52857‏
996 ‎‡2  LC|n 97114654‏
996 ‎‡2  ISNI|0000000069206331‏
996 ‎‡2  PTBNP|101354‏
996 ‎‡2  ISNI|0000000070811387‏
996 ‎‡2  ISNI|0000000069616437‏
996 ‎‡2  DNB|1303550075‏
996 ‎‡2  ISNI|0000000069400177‏
996 ‎‡2  ISNI|0000000069217831‏
996 ‎‡2  ISNI|0000000069933846‏
996 ‎‡2  NUKAT|n 2017017644‏
996 ‎‡2  ISNI|0000000072881741‏
996 ‎‡2  PTBNP|1528633‏
996 ‎‡2  PTBNP|75330‏
996 ‎‡2  DNB|1057410926‏
996 ‎‡2  PTBNP|142765‏
996 ‎‡2  SUDOC|069959188‏
996 ‎‡2  PTBNP|1596675‏
996 ‎‡2  DNB|1306566541‏
996 ‎‡2  PTBNP|820161‏
996 ‎‡2  J9U|987007343166105171‏
996 ‎‡2  CAOONL|ncf10229618‏
996 ‎‡2  ISNI|0000000112869553‏
996 ‎‡2  ISNI|0000000069482723‏
996 ‎‡2  ISNI|0000000070701655‏
996 ‎‡2  NSK|000692786‏
996 ‎‡2  ISNI|0000000024127082‏
996 ‎‡2  ISNI|0000000068006573‏
996 ‎‡2  PTBNP|1590117‏
996 ‎‡2  LC|n 91033077‏
996 ‎‡2  PTBNP|1265515‏
996 ‎‡2  ISNI|0000000115926322‏
996 ‎‡2  PTBNP|1377409‏
996 ‎‡2  ISNI|0000000068915064‏
996 ‎‡2  ISNI|0000000070604599‏
996 ‎‡2  BLBNB|000300998‏
996 ‎‡2  PTBNP|1042401‏
996 ‎‡2  PTBNP|1189185‏
996 ‎‡2  LC|no2013039382‏
996 ‎‡2  SUDOC|131787942‏
996 ‎‡2  PTBNP|1376031‏
996 ‎‡2  ISNI|0000000070531676‏
996 ‎‡2  SUDOC|17758081X‏
996 ‎‡2  PTBNP|1217889‏
996 ‎‡2  DNB|1122703104‏
996 ‎‡2  LC|n 93900547‏
996 ‎‡2  BLBNB|000283551‏
996 ‎‡2  PTBNP|273043‏
996 ‎‡2  PTBNP|1149177‏
996 ‎‡2  PTBNP|823424‏
996 ‎‡2  NII|DA1478507X‏
996 ‎‡2  SUDOC|268683549‏
996 ‎‡2  BLBNB|001510541‏
996 ‎‡2  BLBNB|000601006‏
996 ‎‡2  ISNI|0000000068681851‏
996 ‎‡2  ISNI|0000000070311307‏
996 ‎‡2  PTBNP|28076‏
996 ‎‡2  PTBNP|1770267‏
996 ‎‡2  PTBNP|1264561‏
996 ‎‡2  SUDOC|119551993‏
996 ‎‡2  PTBNP|94386‏
996 ‎‡2  PTBNP|1185682‏
996 ‎‡2  LC|no2005120396‏
996 ‎‡2  ISNI|0000000068908550‏
996 ‎‡2  ISNI|0000000070302822‏
996 ‎‡2  ISNI|0000000068999499‏
996 ‎‡2  PTBNP|82678‏
996 ‎‡2  LC|no2009007477‏
996 ‎‡2  LC|no2012143459‏
996 ‎‡2  DNB|1057387983‏
996 ‎‡2  ISNI|0000000067983348‏
996 ‎‡2  PTBNP|1352093‏
996 ‎‡2  ISNI|0000000069390853‏
996 ‎‡2  PTBNP|1384790‏
996 ‎‡2  ISNI|000000007060867X‏
996 ‎‡2  PTBNP|187727‏
996 ‎‡2  ISNI|0000000069894146‏
996 ‎‡2  ISNI|0000000067988157‏
996 ‎‡2  RERO|A014153989‏
996 ‎‡2  PTBNP|336211‏
996 ‎‡2  PTBNP|1535784‏
996 ‎‡2  ISNI|0000000084366894‏
996 ‎‡2  SUDOC|175404224‏
996 ‎‡2  ISNI|0000000068998701‏
996 ‎‡2  ISNI|0000000068882258‏
996 ‎‡2  PTBNP|1178228‏
996 ‎‡2  ISNI|0000000069695112‏
996 ‎‡2  LC|nb2006017041‏
996 ‎‡2  NSK|000273551‏
996 ‎‡2  SUDOC|241605377‏
996 ‎‡2  PTBNP|1182466‏
996 ‎‡2  BLBNB|001571005‏
996 ‎‡2  ISNI|0000000067679207‏
996 ‎‡2  PLWABN|9814036655005606‏
996 ‎‡2  ISNI|0000000039956617‏
996 ‎‡2  NUKAT|n 2007138229‏
996 ‎‡2  PTBNP|125037‏
996 ‎‡2  ISNI|0000000068702333‏
996 ‎‡2  ISNI|0000000068621461‏
996 ‎‡2  SUDOC|265803829‏
996 ‎‡2  ISNI|0000000070405805‏
996 ‎‡2  SUDOC|189718021‏
996 ‎‡2  ISNI|0000000068311607‏
996 ‎‡2  PTBNP|99216‏
996 ‎‡2  PTBNP|1313171‏
996 ‎‡2  CAOONL|ncf11532419‏
996 ‎‡2  PTBNP|1088313‏
996 ‎‡2  PTBNP|911541‏
996 ‎‡2  BNC|981058520408806706‏
996 ‎‡2  LC|n 92020908‏
996 ‎‡2  SUDOC|253363004‏
996 ‎‡2  PTBNP|1920577‏
996 ‎‡2  SUDOC|11560586X‏
996 ‎‡2  SUDOC|074613510‏
996 ‎‡2  ISNI|000000006992400X‏
996 ‎‡2  ISNI|0000000069727348‏
996 ‎‡2  ISNI|0000000119300853‏
996 ‎‡2  ISNI|0000000069703629‏
996 ‎‡2  ISNI|0000000033216132‏
996 ‎‡2  BNF|16509402‏
996 ‎‡2  PTBNP|1488098‏
996 ‎‡2  PTBNP|1365560‏
996 ‎‡2  LC|no2003124036‏
996 ‎‡2  ISNI|0000000068176708‏
996 ‎‡2  ISNI|0000000072881602‏
996 ‎‡2  NKC|xx0068680‏
996 ‎‡2  ISNI|0000000067980024‏
996 ‎‡2  PTBNP|98809‏
996 ‎‡2  SUDOC|158158695‏
996 ‎‡2  ISNI|0000000032483431‏
996 ‎‡2  PTBNP|1298960‏
996 ‎‡2  BLBNB|000165384‏
996 ‎‡2  BLBNB|001036606‏
996 ‎‡2  BLBNB|000165389‏
996 ‎‡2  BLBNB|000165388‏
996 ‎‡2  ISNI|0000000026748843‏
996 ‎‡2  PTBNP|272037‏
996 ‎‡2  PTBNP|219013‏
996 ‎‡2  ISNI|0000000069421824‏
996 ‎‡2  ISNI|0000000373448378‏
996 ‎‡2  PTBNP|1347128‏
996 ‎‡2  ISNI|0000000428240305‏
996 ‎‡2  LC|no2020008760‏
996 ‎‡2  ISNI|0000000069222593‏
996 ‎‡2  NUKAT|n 2007105093‏
996 ‎‡2  NUKAT|n 2014189297‏
996 ‎‡2  PTBNP|51189‏
996 ‎‡2  CAOONL|ncf11890492‏
996 ‎‡2  PTBNP|24685‏
996 ‎‡2  PTBNP|1931712‏
996 ‎‡2  ISNI|0000000068400626‏
996 ‎‡2  DNB|1235248135‏
996 ‎‡2  ISNI|0000000067446462‏
996 ‎‡2  ISNI|0000000428350678‏
996 ‎‡2  ISNI|000000006768986X‏
996 ‎‡2  ISNI|0000000093758558‏
996 ‎‡2  ISNI|0000000044267277‏
996 ‎‡2  PTBNP|185820‏
996 ‎‡2  PTBNP|74542‏
996 ‎‡2  BLBNB|001030049‏
996 ‎‡2  CAOONL|ncf11319498‏
996 ‎‡2  PTBNP|1744573‏
996 ‎‡2  ISNI|0000000436903607‏
996 ‎‡2  LIH|LNB:BUEG;=1A‏
996 ‎‡2  PTBNP|800425‏
996 ‎‡2  BNF|15051143‏
996 ‎‡2  PTBNP|197783‏
996 ‎‡2  PTBNP|1010379‏
996 ‎‡2  ISNI|000000006929794X‏
996 ‎‡2  BNC|981058527119706706‏
996 ‎‡2  SUDOC|23509417X‏
996 ‎‡2  DNB|1194489427‏
996 ‎‡2  BLBNB|000462297‏
996 ‎‡2  PTBNP|1458782‏
996 ‎‡2  DNB|1056488883‏
996 ‎‡2  LC|no2014057600‏
996 ‎‡2  SUDOC|235301981‏
996 ‎‡2  PTBNP|1790866‏
996 ‎‡2  PTBNP|681466‏
996 ‎‡2  NKC|vse2006351596‏
996 ‎‡2  PTBNP|1476008‏
996 ‎‡2  PTBNP|954408‏
996 ‎‡2  PTBNP|191907‏
996 ‎‡2  PTBNP|248253‏
996 ‎‡2  BLBNB|000396747‏
996 ‎‡2  PTBNP|1011812‏
996 ‎‡2  PTBNP|1333297‏
996 ‎‡2  PTBNP|1842681‏
996 ‎‡2  PTBNP|874226‏
996 ‎‡2  ISNI|0000000070539395‏
996 ‎‡2  PTBNP|51200‏
996 ‎‡2  PTBNP|1195617‏
996 ‎‡2  NUKAT|n 2010301398‏
996 ‎‡2  PTBNP|1365353‏
996 ‎‡2  ISNI|0000000068889281‏
996 ‎‡2  ISNI|0000000069624795‏
996 ‎‡2  ISNI|0000000066346523‏
996 ‎‡2  ISNI|0000000068914977‏
996 ‎‡2  PTBNP|1658569‏
996 ‎‡2  ISNI|0000000051364649‏
996 ‎‡2  PTBNP|1039778‏
996 ‎‡2  PTBNP|1659336‏
996 ‎‡2  ISNI|0000000001537863‏
996 ‎‡2  LC|n 2009003144‏
996 ‎‡2  PTBNP|182358‏
996 ‎‡2  ISNI|0000000383840779‏
996 ‎‡2  RERO|A024949618‏
996 ‎‡2  PTBNP|800076‏
996 ‎‡2  LC|n 88015995‏
996 ‎‡2  ISNI|0000000069519485‏
996 ‎‡2  PTBNP|217730‏
996 ‎‡2  ISNI|000000007052410X‏
996 ‎‡2  PTBNP|943577‏
996 ‎‡2  PTBNP|1405939‏
996 ‎‡2  LC|n 88126103‏
996 ‎‡2  DNB|1056542888‏
996 ‎‡2  SUDOC|256321183‏
996 ‎‡2  LNB|LNC10-000028385‏
996 ‎‡2  BLBNB|001511820‏
996 ‎‡2  PTBNP|1668963‏
996 ‎‡2  ISNI|000000007090388X‏
996 ‎‡2  PTBNP|31107‏
996 ‎‡2  LC|n 2014205888‏
996 ‎‡2  PTBNP|1267788‏
996 ‎‡2  ISNI|0000000403630593‏
996 ‎‡2  ISNI|0000000067566245‏
996 ‎‡2  PTBNP|1195548‏
996 ‎‡2  SUDOC|069553785‏
996 ‎‡2  ISNI|0000000070398465‏
996 ‎‡2  PTBNP|1420688‏
996 ‎‡2  ISNI|0000000068993169‏
996 ‎‡2  ISNI|0000000068382237‏
996 ‎‡2  PTBNP|1150613‏
996 ‎‡2  SUDOC|146948874‏
996 ‎‡2  PTBNP|1281231‏
996 ‎‡2  PTBNP|1461248‏
996 ‎‡2  PTBNP|1878460‏
996 ‎‡2  NSK|000657301‏
996 ‎‡2  BLBNB|001478115‏
996 ‎‡2  ISNI|000000007043530X‏
996 ‎‡2  ISNI|0000000068913595‏
996 ‎‡2  PTBNP|1195646‏
996 ‎‡2  ISNI|0000000070941851‏
996 ‎‡2  PTBNP|1224609‏
996 ‎‡2  SUDOC|153233540‏
996 ‎‡2  PTBNP|1381746‏
996 ‎‡2  ISNI|0000000070193929‏
996 ‎‡2  LC|no2010077180‏
996 ‎‡2  PTBNP|233558‏
996 ‎‡2  NII|DA12129627‏
997 ‎‡a  0 0 lived 0 0‏ ‎‡9  1‏